Moderna, Inc.
200.10USD
-2.5300 (-1.25%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on MRNA.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 145 | 389 | 678 | 1,016 | 142 | 108 | 966 | 1,862 |
| Cost of Revenue | 93 | 955 | 452 | 207 | 119 | 90 | 739 | 514 |
| Gross Profit | 52 | -566 | 226 | 809 | 23 | 18 | 227 | 1,348 |
| Operating Income | -815 | -1,388 | -857 | -260 | -907 | -1,050 | -1,246 | -70 |
| Net Income | -782 | -1,343 | -826 | -200 | -825 | -971 | -1,120 | 13 |
| EPS (Diluted) | -$1.97 | -$3.40 | -$2.11 | -$0.51 | -$2.13 | -$2.52 | -$2.91 | $0.03 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)